LONDON and KOBE, Japan, Nov. 9, 2026 — Hologen (HQ: London, UK; CEO: Roland Tegeder), a frontier AI company, and Sysmex Corporation (HQ: Kobe, Japan; President: Iwane Matsui), a global leader in hematology, today announced Saibogen, a blood intelligence company formed as a joint venture between the two companies. Saibogen will apply Hologen’s Large Medicine Models, generative AI models that learn the biology underpinning real-world healthcare data, to proprietary data generated by Sysmex hematology analyzers. The approach aims to unlock new insights from routine blood testing data, with no new instruments, reagents or samples, and to create new clinical value for healthcare professionals and researchers.
Hematology testing is one of the most widely performed laboratory investigations worldwide and often serves as a starting point for medical care. Sysmex hematology analyzers alone run approximately 3 billion¹ of these tests each year, producing a precise, standardized set of values that clinicians around the world rely on. With Saibogen, Sysmex and Hologen are launching a mission to uncover the hidden biological signals in data that Sysmex hematology analyzers already generate.
Saibogen’s ambition is to change what a hematology analyzer is for: from an instrument that reports a standard panel of parameters to a platform that delivers rich and dynamic biological insight without compromising accessibility. Saibogen will deliver these insights to its partners in healthcare and clinical research from tests they already perform, helping them bring more predictive, preventive and personalized care to patients worldwide.
Saibogen brings together the strengths of Sysmex and Hologen, creating a company with a unique opportunity to improve healthcare. Sysmex brings extensive expertise in hematology, proprietary data, product development capabilities and a global business platform. Hologen contributes more than a decade of fundamental research by its scientific co-founders into applying AI to the most challenging data in medicine. Building on early collaborative research by Hologen and Sysmex, and on the companies’ access to routine blood data at scale, Saibogen will deliver its blood intelligence products as software exclusively through Sysmex’s hematology analyzers. Saibogen’s first offerings will be for research use only.
“What if a routine blood test were also one of the most informative in medicine?” said Leila Luheshi, CEO of Saibogen. “Every routine blood count measures tens of thousands of cells with remarkable precision, and much of that information goes unused. We are building the AI to read it in full, so researchers, laboratories and clinicians can learn far more from a test that is already part of everyday care.”
“Every day, laboratories around the world rely on Sysmex hematology analyzers to support clinical decision-making,” said Iwane Matsui, president of Sysmex Corporation. “Over decades, Sysmex has built not only deep expertise in hematology, but also a global business platform through which high-quality, standardized hematology data is generated every day. Through Saibogen, we aim to combine this foundation with Hologen’s AI technologies to unlock new value from routine blood testing data and support researchers, healthcare professionals, and ultimately patients.”
“Blood is one of the richest sources of biological information we have,” said Roland Tegeder, CEO of Hologen. “Our Large Medicine Models are built to learn that biology from real-world data. Working with Sysmex, Saibogen can apply them at global scale and turn the most routine measurement in medicine into blood intelligence that researchers and clinicians can act on.”
¹ Based on Sysmex research. The number of CBC tests, calculated based on reagent consumption, is monitored as one of the key performance indicators (KPIs) for Sysmex’s sustainability targets. See Sysmex Sustainability: Materiality.
The information contained in this press release is current as of the date of the announcement but may be subject to change without prior notice.
###